GKOS vs. WST, BAX, PODD, SWAV, TFX, SOLV, GMED, PEN, STVN, and MMSI
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include West Pharmaceutical Services (WST), Baxter International (BAX), Insulet (PODD), Shockwave Medical (SWAV), Teleflex (TFX), Solventum (SOLV), Globus Medical (GMED), Penumbra (PEN), Stevanato Group (STVN), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Glaukos (NYSE:GKOS) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
In the previous week, Glaukos had 15 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 20 mentions for Glaukos and 5 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.71 beat Glaukos' score of 0.84 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.
Glaukos presently has a consensus target price of $112.27, indicating a potential downside of 1.44%. West Pharmaceutical Services has a consensus target price of $435.20, indicating a potential upside of 38.30%. Given West Pharmaceutical Services' higher possible upside, analysts plainly believe West Pharmaceutical Services is more favorable than Glaukos.
West Pharmaceutical Services has a net margin of 19.42% compared to Glaukos' net margin of -43.15%. West Pharmaceutical Services' return on equity of 20.57% beat Glaukos' return on equity.
99.0% of Glaukos shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Glaukos received 165 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. Likewise, 64.70% of users gave Glaukos an outperform vote while only 55.74% of users gave West Pharmaceutical Services an outperform vote.
West Pharmaceutical Services has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
Glaukos has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Summary
Glaukos and West Pharmaceutical Services tied by winning 9 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
